• Advertise
  • Contact Us
  • Daily The Business
  • Privacy Policy
Thursday, February 5, 2026
Daily The Business
  • Login
No Result
View All Result
DTB
No Result
View All Result
DTB

India flags quality issues with some widely used antacids and paracetamol

September 27, 2024
in World
India flags quality issues with some widely used antacids and paracetamol
Share on FacebookShare on TwitterWhatsapp

BENGALURU: India’s drug regulator has found more than 50 drugs, including some batches of widely used antacids and paracetamol, to be substandard or fake, according to government documents.

The regulator, Central Drugs Standard Control Organisation, releases a monthly list of substandard or fake medicines sold in the country after routine tests across the country by multiple agencies.

The regulator found some drugs as “not of standard quality”, including a batch each of Alkem Laboratories’ popular antacid Pan-D, Hetero’s anti-infective Cepodem and Shelcal, a vitamin and calcium tablet brand made by privately-owned Pure & Cure Healthcare, and several antibiotics, according to the lists for August.

Sun Pharmaceutical Industries separately informed the regulator of a fake batch of Pantocid, a popular Indian brand of an antacid called pantoprazole. The agency said it is investigating the matter. Fake, or “spurious”, batches of Sun’s drug Pulmosil, used to treat high blood pressure in the lungs, and Glenmark Pharmaceuticals’ anti-hypertension drug Telma H, among others, were also notified by the companies to the regulator and were being investigated.

“When a medicine is found to be below quality standards, the drug regulator sends a notice to the manufacturer to check and recall that batch of product. Companies too conduct their own tests on leftover samples to check for the possibility of counterfeit,” said Rajiv Singhal, general secretary of drug retailer body All India Organisation of Chemists and Druggists.

Pharma industry: Govt reaffirms pledge to provide conducive environment

The companies did not immediately respond to Reuters’ request for comment. Gastrointestinal, anti-diabetic, vitamins and nutraceutical drug sales were one of the top contributors to the domestic pharma market growth in August, according to research firm Pharmarack.

India, one of the world’s largest drug producers and exporters, is working to restore confidence after Indian-made cough syrups were linked to the deaths of children in Gambia, Uzbekistan, and Cameroon.

Tags: All India Organisation of Chemists and DruggistsantacidsIndiaIndia drug regulatorparacetamol
Share15Tweet10Send
Previous Post

Israel rejects US-backed Lebanon ceasefire plan, hits Beirut again

Next Post

What obstacles stand in the way of an Israel-Hezbollah cease-fire?

Related Posts

Donors reluctant to fund US-led Gaza plan
World

Donors reluctant to fund US-led Gaza plan

February 5, 2026
Washington Post cuts staff, shrinks news coverage
World

Washington Post cuts staff, shrinks news coverage

February 5, 2026
US pushes to widen talks with Iran beyond nuclear issue despite Tehran’s refusal
World

US pushes to widen talks with Iran beyond nuclear issue despite Tehran’s refusal

February 5, 2026
Xi and Trump talk by phone, Chinese state media report
World

Xi and Trump talk by phone, Chinese state media report

February 4, 2026
Indian minister says ‘sensitive’ sectors protected in US trade deal
World

Indian minister says ‘sensitive’ sectors protected in US trade deal

February 4, 2026
Trump’s India pact to make big dent in Russian oil revenue
World

Trump’s India pact to make big dent in Russian oil revenue

February 4, 2026

Popular Post

  • FRSHAR Mail

    FRSHAR Mail set to redefine secure communication, data privacy

    127 shares
    Share 51 Tweet 32
  • How to avoid buyer’s remorse when raising venture capital

    33 shares
    Share 337 Tweet 211
  • Microsoft to pay off cloud industry group to end EU antitrust complaint

    55 shares
    Share 22 Tweet 14
  • Capacity utilisation of Pakistan’s cement industry drops to lowest on record

    48 shares
    Share 19 Tweet 12
  • SingTel annual profit more than halves on $2.3bn impairment charge

    48 shares
    Share 19 Tweet 12
American Dollar Exchange Rate
  • Advertise
  • Contact Us
  • Daily The Business
  • Privacy Policy
Write us: info@dailythebusiness.com

© 2021 Daily The Business

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist

No Result
View All Result
  • Advertise
  • Contact Us
  • Daily The Business
  • Privacy Policy

© 2021 Daily The Business

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.